

## **SHORT CV**

---

**Emilia Hadziyannis**

**Assistant Professor of Clinical Pathology- Clinical Microbiology**  
**2<sup>nd</sup> Dpt of Internal Medicine and Laboratory, National and Kapodistrian**  
**University of Athens, School of Medicine**  
**63-67 Evrou Str**  
**115 27, Athens**  
**Greece**  
**Tel: +30 213-2088603**  
**Fax: +30 213-2088601**  
**Mobile: +30 693-6455492**

Female – Married (2 children)

### **Current Position**

Assistant Professor of Clinical Pathology- Clinical Microbiology  
Responsible for Hepatology – Immunology Laboratory of the 2<sup>nd</sup> Dpt of  
Internal Medicine in Hippokratio Hospital, Athens Greece  
Patient Services and Research: Molecular Diagnostics, Flow Cytometry,  
Elispot, Cell culture, EIA, Nephelometry, Immunofluorescent Microscopy,  
Microscopy and Biochemical analyses.

### **Education - Training**

**1983-89:** National and Kapodistrian University of Athens, School of Medicine  
**1990-1996:** Doctorate Thesis, National and Kapodistrian University of Athens,  
School of Medicine  
**5/92-8/92:** Visitor Immunodiagnostic Laboratory, Department of  
Hepatology/GI and AIDS, Baylor College of Medicine, Houston, TX  
**8/92-4/94:** Research Fellow National Cancer Institute - FCRDC,  
ABL - Basic Research Program, Molecular Mechanisms of Carcinogenesis  
Laboratory, Human Retroviruses Section, Frederick, MD, USA

**7/94-6/97:** Resident Department of Pathology and Laboratory Medicine, Emory University Hospitals, Atlanta, GA, USA. Chief resident (1996-97). Board Certification in Clinical Pathology, The American Board of Pathology.  
**7/97-6/99:** Fellow in Clinical Microbiology Department of Clinical Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA.

### **Academic Positions**

**2009- today** Assistant Professor of Clinical Pathology- Clinical Microbiology 2<sup>nd</sup> Dpt of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine

**2003- 2009** Lecturer of Clinical Pathology- Clinical Microbiology 2<sup>nd</sup> Dpt of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine

**1999-2003** Scientific associate 2<sup>nd</sup> Dpt of Internal Medicine and Hepatology Laboratory, National and Kapodistrian University of Athens

### **Publications in Medical Journals**

h Factor (Scopus): **17**

1. In press: George Papatheodoridis, Christos Triantos, Emilia Hadziyannis, Konstantinos, Zisimopoulos, Anastasia Georgiou, Theodoros Voulgaris, Ioannis, Vlachogiannakos, Vasiliki Nikolopoulou, Spilios Manolakopoulos. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate *Journal of Viral Hepatitis*
2. Petraki A, Kittou N, Hadziyannis E, Dourakis SP. Cryoglobulinemic purpura in visceral leishmaniasis. *J Infect.* 2015 Mar 12. pii: S0163-4453(15)00076-6. doi:10.1016/j.jinf.2015.03.002. [Epub ahead of print]
3. Chondrogiannis K, Hadziyannis E, Fassoulaki A. Propofol or sevoflurane anaesthesia does not affect hepatic integrity as assessed by the M30 & M65 cell death markers & liver enzymes. *Indian J Med Res.* 2014 Nov;140(5):630-6.
4. Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G, Vassilopoulos D. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with

rheumatic diseases. *Ann Rheum Dis*. 2014 May 22. pii: annrheumdis-2014-205376. doi:10.1136/annrheumdis-2014-205376. [Epub ahead of print]

5. Hadziyannis SJ, Laras A, Hadziyannis E. Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? *Aliment Pharmacol Ther*. 2014 May;39(10):1250-1.
6. Hadziyannis, S.J. , Vassilopoulos, D., Sevastianos, V., Hadziyannis, E. Can nucleos(T)ide analogue (na) therapy ever be stopped in HBeAg-negative chronic hepatitis B? *Current Hepatitis Reports Volume 13, Issue 3, 17: 256-263, 2014*
7. Konstantinou D, Margariti E, Hadziyannis E, Pectasides D, Papatheodoridis GV. Significance of the (13)C-caffeine breath test for patients with cirrhosis. *Ann Gastroenterol*. 2014;27(1):53-59.
8. Vasileiou P, Tsioufis C, Lazaros G, Hadziyannis E, Kasiakogias A, Stefanadis C, Kallikazaros I, Vassilopoulos D. Interleukin-8 as a predictor of acute idiopathic pericarditis recurrences. A pilot study. *Int J Cardiol*. 2014 Apr 1;172(3):e463-4.
9. Hadziyannis E, Hadziyannis SJ. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility. *Expert Rev Gastroenterol Hepatol*.2014 Feb;8(2):185-95
10. Hadziyannis SJ, Vassilopoulos D, Hadziyannis E. The natural course of chronic hepatitis B virus infection and its management. *Adv Pharmacol*. 2013;67:247-91.
11. Deutsch M, Papadopoulos N, Hadziyannis ES, Koskinas J. Clinical characteristics, spontaneous clearance and treatment outcome of acute hepatitis C: a single tertiary center experience. *Saudi J Gastroenterol*. 2013 Mar-Apr;19(2):81-5.
12. Minopetrou M, Hadziyannis E, Deutsch M, Tampaki M, Georgiadou A, Dimopoulou E, Vassilopoulos D, Koskinas J. Hepatitis C virus (HCV)-related cryoglobulinemia: cryoglobulin type and anti-HCV profile. *Clin Vaccine Immunol*. 2013 May;20(5):698-703.
13. Hadziyannis E. Quantification of HBsAg in serum: characteristics of the assays. *OA Hepatology Apr 01;1(1):1, 2013*

14. Emilia Hadziyannis, Konstantinos Sialevrakis, Anastasia Georgiou, John Koskinas. Analysis of serum  $\alpha$ -fetoprotein-L3% and des- $\gamma$  carboxyprothrombin markers in cases with misleading for hepatocellular carcinoma total  $\alpha$ -fetoprotein levels. *Oncol Rep.* 2013 Feb;29(2):835-9
15. E. Hadziyannis, M. Minopetrou, A. Georgiou, F. Spanou, J. Koskinas. Is HCV Core Ag a Reliable Marker of Viral Load? Comparison of an HCV Core Antigen Automated Immunoassay to Quantitative HCV RNA in Chronic Hepatitis C. *Annals of Gastroenterology*,26:1-4, 2013
16. Ioannis Mitroulis, Chrisoula Chatzara, Anna Kandili, Emilia Hadziyannis, Dimitrios Vassilopoulos Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. *Ann Rheum Dis* 2013 Feb;72(2):308-10.
17. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients with Chronic Hepatitis B Who Stop Long-Term Treatment with Adefovir. *Gastroenterology*, 2012 143 (3): 629-636.
18. Giannousis IP, Manolakopoulos SG, Hadziyannis E, Georgiou A, Papatheodoridis GV. Changes of serum levels of keratin-18 fragments in hepatitis B e antigen-negative chronic hepatitis B patients under oral antiviral therapy. *Antivir Ther.* 2011;16(4):505-1
19. Manesis EK, Papatheodoridis GV, Tiniakos DG, Hadziyannis ES, Agelopoulou OP, Syminelaki T, Papaioannou C, Nastos T, Karayiannis P. Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. *J Hepatol.* 2011 Jul;55(1):61-8
20. Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. *Clin Vaccine Immunol.* 2011 Dec;18(12):2102-8.
21. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, Margariti K, Manolakopoulos S, Manesis EK, Archimandritis AJ. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease. *J Clin Gastroenterol.* 2010 Apr;44(4):e87-95

22. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, Manesis EK, Archimandritis AI. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. *Ann Rheum Dis.* 2010 Jul;69(7):1352-5
23. Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, Mamalaki A, Archimandritis AJ. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. *J Viral Hepat.* 2010 Nov;17(11):800-6
24. Schina M, Koskinas J, Tiniakos D, Hadziyannis E, Savvas S, Karamanos B, Manesis E, Archimandritis A. Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. *Hepatol Res.* 2009 Oct;39(10):972-8.
25. Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, Hadziyannis E, Triantos C, Zisimopoulos K, Goulis I, Tzourmakliotis D, Akriviadis E, Manesis EK, Archimandritis AJ. Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. *Aliment Pharmacol Ther.* 2009 Nov 1;30(9):947-54.
26. Emilia Hadziyannis, Dimitrios Vassilopoulos and Stephanos J. Hadziyannis, Quantitative HBsAg titer as predictor of response to therapy *Current Hepatitis Reports* 2009 Volume 8, Number 4, 169-172
27. Papatheodoridis GV, Chrysanthos N, Hadziyannis E, Cholongitas E, Manesis EK. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. *J Viral Hepat* 15 (6): 434-441, 2008
28. Hadziyannis E, Manesis E, Vassilopoulos D, Georgiou A, Archimandritis A. Performance characteristics of microparticle enzyme and chemiluminescence immunoassays for measurement of anti-HBc immunoglobulin M in sera of patients with HBeAg-negative chronic hepatitis B virus infection. *Clin Vaccine Immunol.* 2008 Feb;15(2):385-7
29. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of Enzyme-Linked Immunospot Assay (Elispot) Compared to Tuberculin Skin Testing for Latent Tuberculosis Screening in Rheumatic

Patients Scheduled for Anti-Tumor Necrosis Factor Treatment. *J Rheumatol.* 2008 Mar 15.

30. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Tiniakos DG, Giannousis I, Manesis EK, Archimandritis AJ. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. *Gut.* 2008 Apr;57(4):500-6.
31. Vassilopoulos D, Rapti I, Nikolaou M, Hadziyannis E, Hadziyannis SJ. Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B. *J Viral Hepat.* 2008 Nov;15(11):817-26.
32. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, Georgiou A, Kafiri G, Tiniakos DG, Manesis EK, Archimandritis AJ. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. *Scand J Gastroenterol.* 2008;43(9):1128-36.
33. Papatheodoridis, G.V., Hadziyannis, E., Tsochatzis, E., Georgiou, A., Kafiri, G., Manolakopoulos, S., Manesis, E.K., Archimandritis, A.J. Serum apoptotic caspase activity as a marker of severity in chronic hepatitis C virus infection *Annals of Gastroenterology* 21 (1): 39-44, 2008
34. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, Hadziyannis E, Pandelidaki H, Zafiropoulou R, Savvas S, Koskinas J, Archimandritis AJ. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. *Am J Gastroenterol.* 2007 Mar;102(3):634-41
35. Deutsch M, Manesis EK, Hadziyannis E, Vassilopoulos D, Archimandritis AJ. Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b. *Scand J Gastroenterol.* 2007 Mar;42(3):408-9
36. Koskinas J, Kilidireas C, Karandreas N, Kountouras D, Savvas S, Hadziyannis E, Archimandritis AJ. Severe hepatitis C virus-related cryoglobulinaemic sensory-motor polyneuropathy treated with pegylated interferon-a2b and ribavirin: clinical, laboratory and neurophysiological study. *Liver Int.* 2007 Apr;27(3):414-20.
37. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic

- hepatitis B: a clue from serum HBsAg levels. *Antivir Ther.* 2007;12(1):73-82.
38. Tsochatzis E, Vassilopoulos D, Manesis EK, Papatheodoridis G, Bousiotou A, Hadziyannis E, Archimandritis AJ. First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. *Scand J Gastroenterol.* 2007 Jun;42(6):784-5
  39. Manesis EK, Schina M, Le Gal F, Agelopoulou O, Papaioannou C, Kalligeros C, Arseniou V, Manolakopoulos S, Hadziyannis ES, Gault E, Koskinas J, Papatheodoridis G, Archimandritis AJ. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. *Antivir Ther.* 2007;12(3):381-8.
  40. Procop GW, Tuohy MJ, Wilson DA, Williams D, Hadziyannis E, Hall GS. Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*. *Am J Clin Pathol.* 2003 Aug;120(2):265-7
  41. Vassilopoulos D, Younossi ZM, Hadziyannis E, Boparai N, Yen-Lieberman B, Hsi E, Villa-Forte A, Ball E, Kimberly RP, Calabrese LH. Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations. *Clin Exp Rheumatol.* 2003 Nov-Dec;21(6 Suppl 32):S101-11
  42. G.V. Papatheodoridis, E. Hadziyannis, M. Deutsch, S.J. Hadziyannis. Ursodeoxycholic acid for Primary Biliary Cirrhosis: Final results of a 12-year prospective, randomized, controlled trial. *Am J Gastroenterol* 2002 Aug; 97(8): 2063-70.
  43. Hadziyannis E, Hadziyannis A, Yen-Lieberman B, Kiwi ML, Hodnick S, Spanou F, Starkey C, Younossi ZM. Hepatitis C virus RNA assays: a comparison of SuperQuant and Monitor. *J Clin Gastroenterol.* 2001 Jul;33(1):45-8.
  44. Hadziyannis E, Tuohy M, Thomas L, Procop GW, Washington JA, Hall GS. Screening and confirmatory testing for extended spectrum beta-lactamases (ESBL) in *Escherichia coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca* clinical isolates. *Diagn Microbiol Infect Dis* 2000; 36: 113-117.

45. Hadziyannis E, Yen-Lieberman B, Hall G, Procop GW. Ciliocytophthoria in clinical virology. *Arch Pathol Lab Med*. 2000 Aug;124(8):1220-3.
46. Hadziyannis E, Sholtis W, Schindler S, Yen-Lieberman B. Comparison of VIDAS with direct immunofluorescence for the detection of respiratory syncytial virus in clinical specimens. *J Clin Virol* 1999; 14:133-136.
47. Hadziyannis E, Cornish N, Starkey C, Procop GW, Yen-Lieberman B. Amplicor enterovirus polymerase chain reaction in patients with aseptic meningitis: a sensitive test limited by amplification inhibitors. *Arch Pathol Lab Med* 1999; 123:882-884.
48. Hadziyannis E, Fried MW, Nolte FS. Evaluation of Two Methods for Quantitation of Hepatitis C Virus RNA. *Mol Diagn* 1997; 2:39-46. (current title *Molecular Diagnosis & Therapy*)
49. Saltarelli MJ, Hadziyannis E, Hart CE, Harrison JV, Felber BK, Spira TJ, Pavlakis GN. Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals. *AIDS Res Hum Retroviruses* 1996; 12:1443-1456.
50. Neumann M, Harrison J, Saltarelli M, Hadziyannis E, Erfle V, Felber BK, Pavlakis GN. Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction. *AIDS Res Hum Retroviruses* 1994; 10:1531-1542.
51. S.J. Hadziyannis, G. Giannoulis, E. Hadziyannis, E. Kaklamani, A. Alexopoulou, S. Dourakis, D. Trichopoulos. Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma. *J Hepatol*.17 Suppl 3:S72-S77, 1993
52. Hadziyannis SJ, Dourakis SP, Papaioannou C, Alexopoulou A, Hadziyannis ES, Gioustozi A. Changing epidemiology and spreading modalities of hepatitis delta virus infection in Greece. *Prog Clin Biol Res* 382:259-266, 1993.

### **Book Chapters**

1. A Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid. The third year of a controlled trial (1990).Hadziyannis, S.,



- Hadziyannis, E.S., Lianidou, E., Makris. Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice, pp. 287-296
2. Check Sample on Drug Resistant Candida Species. E. Hadziyannis and G. S. Hall. ASCP (MB 99-7) Microbiology Volume 42. ASCP, 1999
  - HIV Virology in HIV Infection. AIDS. Kaloterakis A. et al. Paschalidis ed. p. 35-40, Athens 1999.
  3. Herpes viruses Infections 2<sup>nd</sup> ed. Internal Medicine, Department of Internal Medicine National and Kapodistrian University of Athens, School of Medicine Paschalidis ed. p 970-983, 2010.
  4. Molecular Diagnosis of Infectious Diseases. 2<sup>nd</sup> ed. Internal Medicine, Department of Internal Medicine National and Kapodistrian University of Athens, School of Medicine Paschalidis ed. p: 32-36., 2010.
  5. Herpes viruses Infections 3rd ed. Internal Medicine, Department of Internal Medicine National and Kapodistrian University of Athens, School of Medicine, in press
  6. Liver Diseases. Evaluation of laboratory tests. 3rd ed. Internal Medicine, Department of Internal Medicine National and Kapodistrian University of Athens, School of Medicine, in press

### **Abstracts in International Medical Conferences**

1. S.J. Hadziyannis and E. Hadziyannis. A randomized controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC). 39th annual meeting of AASLD. 1421 abstr Hepatology 8: (5) 1421-1421 Sep-Oct 1988.
2. S.J. Hadziyannis and E. Hadziyannis and A. Makris. A randomized controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) 40th annual meeting of AASLD Hepatology 10: 580 abstr.1989.
3. E. Hadziyannis, A. Alexopoulou, T. Bramou, E. Psalidaki, S. J. Hadziyannis. Anti-HCV C100-3 prevalence and titers in chronic NANB hepatitis before and after  $\alpha$ -interferon treatment 26<sup>th</sup> Meeting of EASL, Palma de Mallorca, Spain. abstr. 111, J Hepatol 13: S129, Sept 1991.
4. S.J. Hadziyannis, A. Georgiou, E. Hadziyannis, A. Alexopoulou, S. Dourakis. Serum anti-HBc IgM levels in establishing the etiology of liver-

- cell damage in the anti-HBe positive chronic hepatitis B virus infection. 42nd annual meeting of AASLD abstr. 143, Hepatology; 14:83A, 1991.
5. E. Hadziyannis, A. Alexopoulou, T. Bramou, C. Papaioannou, S.J.Hadziyannis. Serum anti- c100-3 titers in chronic active hepatitis type C and their relation to a-interferon therapy response. 42nd annual meeting of AASLD, abstr. 111, Hepatology 14:75A.1991.
  6. S.J. Hadziyannis, C. Papaioannou, A. Alexopoulou, E. Hadziyannis, S. Dourakis, A. Gioustozi. Changing Epidemiology and modes of transmission of HDV infection in Greece. 4th International Symposium on Hepatitis Delta Virus and Liver Disease, Rhodes, Greece. Abstr. OR-19.,June 8-10 1992.
  7. E. Hadziyannis, A. Weiner, C. Papaioannou, E. Psalidaki, G. Kuo, D. Chien, M. Urdea, J. Wilbur and S.J. Hadziyannis. Antibodies to linear epitopes of HCV and HCV-RNA levels in chronic HCV infection. 43rd annual meeting of the AASLD, abstr. 252. Hepatology;16,4,2:107A 1992.
  8. S.J. Hadziyannis, E. Hadziyannis, A. Georgiou, K. Avgidis, A. Alexopoulou and P. Karayiannis. HBV reactivation in anti-HBe positive HBsAg carriers. 43rd annual meeting of the American Association for the Study of Liver Diseases (AASLD), abstr. 80 Hepatology;16,4,2:64A, 1992.
  9. M. Saltarelli, M. Neumann, E. Hadziyannis, J. Turpin, A. Hatzakis, G. Shaw, G.C. Graziozi, A.S. Fauci, G.N. Pavlakis. Quantitative measurement of all HIV-1 mRNAs in patient cells. IX International Conference on AIDS, abstr. WS-B35-1, Berlin, Germany, June 6-11, 1993.
  10. M.J Saltarelli, E. Hadziyannis, C..E. Hart, B.K.Felber, T.J. Spira, M. Neumann, and G.N. Pavlakis.. Analysis of Complete HIV-1 Transcriptional Profiles of Peripheral Blood Mononuclear Cells (PBMC) from Infected Individuals. Retroviruses, Cold Spring Harbor Laboratory, May 24-May 29, 1994.
  11. E. Hadziyannis, J. Harrison, C. Palamarou, G.N. Pavlakis and S.J. Hadziyannis. Expression of interferon and an interferon inducible gene in the PBMC of patients with chronic viral hepatitis. 45th annual meeting of the AASLD, abstr. 443. Hepatology;20,4,2:207A, 1994.

12. E. Hadziyannis, M. Fried, and F. Nolte. Evaluation of two methods for quantitation of hepatitis C virus (HCV) RNA. 46th annual meeting of the AASLD, Hepatology 22: (4) 1000-1000, Part 2, Suppl. S Oct 1995.
13. J. A. Jernigan, E. Hadziyannis, S.C. Schwarzmann, F.S. Nolte. Vancomycin-Resistant *Enterococcus faecium* (VRE) bacteremia in severely neutropenic patients. 36th ICAAC. Abstract J8 pg.219. September 1996.
14. E. Hadziyannis, N. Larsen, C. Thurmond, D. Maurer and F. Nolte. Genotyping of Hepatitis C Virus with direct sequencing. Comparison with a line probe assay. Association for Molecular Pathology annual meeting. AJP, vol. 151. No 5 pg 1497. Abstract ID14, November 1997.
15. E. Hadziyannis, N. Cornish, C. Starkey and B. Yen-Lieberman. Detection of Enterovirus in Cerebrospinal Fluid by PCR. Comparison with Cell Culture. 98<sup>th</sup> General Meeting of the American Society for Microbiology, Atlanta GA. Abstract C-401 pg.197. May 1998.
16. E. Hadziyannis, Z.M. Younossi, M. Kiwi, S. Hodnick, C. Starkey, B. Yen-Lieberman. Comparison of two PCR-based methods for the quantitation of Hepatitis C Virus RNA. 49th Annual Meeting of the American Association for the Study of Liver Diseases, Abstr 1233. Hepatology 1998, 28: No 4, Pt 2, 1998.
17. S. Schindler, W. Sholtis, E. Hadziyannis, D. Scholl, B. Yen-Lieberman. Rapid Detection of Respiratory Viruses Using A Mink Lung/A549 Mixed Cell Line. Clinical Virology Symposium, Clear Water, Florida, May 1999.
18. E. Hadziyannis, M. Tuohy, L. Thomas, G.W. Procop, J.A. Washington, G.S. Hall Screening and confirmatory testing for extended spectrum beta-lactamases (ESBL) in *E. coli*, *Klebsiella pneumoniae*, and *Klebsiella oxytoca* clinical isolates. 98<sup>th</sup> General Meeting of the American Society for Microbiology, Chicago, IL. Abstract C-254 pg.155-6. June 1999.
19. D Vassilopoulos, Z.M Younossi, E Hadziyannis, N Boparai ,T Greanlich., B Yen-Lieberman, E Hsi, D Cook, E Ball, R Kimberly, L.H. Calabrese. Patterns of immune activation in hepatitis C infection associated with or without autoimmune manifestations. 50th Annual Meeting of the American Association for the Study of Liver Diseases abstr. 790. Hepatology;30, No 4, Pt 2:358A, 1999.

20. G.V. Papatheodoridis, M. Deutsch, E. Hadziyannis, A. Tzakou, S.J. Hadziyannis. Ursodeoxycholic acid for Primary Biliary Cirrhosis: Final results of a 12-year prospective, randomized, controlled trial. *J Hepatol* 17 Suppl 2:40, WP2/16, 2000
21. Vassilopoulos D., Younossi Z.M., Hadziyannis E., Boparai N., Gramlich T., Yen-Lieberman B., Hsi E., Cook D., Ball E., Kimberly R., Villa-Forte A., Calabrese L.H: Immunologic determinants of clinical autoimmune manifestations in chronic HCV infection. 64<sup>th</sup> Annual Scientific Meeting of the American College of Rheumatology, Philadelphia, PA, USA, October 28-November 2, 2000.
22. S. M. Schroeder, E. Hadziyannis, N. E. Cornish, J. A Washington. Comparison of Abbott TestPack + Plus Strep A with Biostar Acceava Strep A Tests for Laboratory Diagnosis of Streptococcal Pharyngitis 99<sup>th</sup> General Meeting of the American Society for Microbiology.2000 (5/21/00 through 5/25/00)
23. Marion J. Tuohy, D. A. Wilson, E. Hadziyannis, Gary W. Procop, Gerri S. Hall. Cross Resistance to Antimicrobials and Confirmatory Testing of ESBL Producing *Klebsiella pneumoniae*. 99<sup>th</sup> General Meeting of the American Society for Microbiology 2001 (5/20/01 through 5/24/01)
24. Emilia Hadziyannis, Fotini Spanou, Aggeliki Kostamena, Savvas Savvas, Stephanos J Hadziyannis. Performance of Transcription Mediated Amplification (TMA) in the Determination of Virological Response to Treatment In Patients With Chronic Hepatitis C. 50th Annual Meeting of the American Association for the Study of Liver Diseases abstr. 207. *Hepatology*; 34, No 4, Pt 2: 225A, 2001
25. Hadziyannis E, Savvas S, Koskinas J, Hadziyannis SJ. Striking changes in the prevalence of hepatitis C virus genotypes in Greece in the last five years. 15<sup>th</sup> European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2005 (CMI Vol.11 S2:201 – P696 April 2005)
26. Hadziyannis A, Panopoulou E, Laras A, Hadziyannis E, Golucci G, Hadziyannis SJ. Quantification of serum HBV-DNA with Cobas Taqman for the diagnosis, monitoring and prognosis of chronic hepatitis B virus infection . 15<sup>th</sup> European Congress of Clinical Microbiology and Infectious

Diseases, Copenhagen, Denmark, April 2005 (CMI Vol.11 S2:494 – P1523 April 2005)

27. Manesis EK, Hadziyannis E, Angelopoulou OP, Hadziyannis SJ. HbsAg levels under interferon and lamivudine therapy in HbeAg-negative chronic hepatitis B (CHBe-) patients. *J Hepatol*;(Suppl 2):S185, 2005
28. Manesis EK, Hadziyannis E, Angelopoulou OP, Hadziyannis SJ. Pretreatment HBsAg serum levels predict HBsAg seroconversion in HBeAg-negative chronic hepatitis B (CHBe-) patients. 55th Annual Meeting of the American Association for the Study of Liver Diseases abstr. 1002. *Hepatology* 42, No 4, P590A, 2005
29. Hadziyannis A, Mitsoula P, Hadziyannis E, Colucci G, Hadziyannis SJ. Monitoring serum HBV-DNA levels with the TAQMAN technique during treatment of HBeAg (-) chronic hepatitis B with lamivudine. 55th Annual Meeting of the American Association for the Study of Liver Diseases abstr. 1339. *Hepatology* 42, No 4, P727A:, 2005
30. Papatheodoridis G, Hadziyannis E, Chrysanthos N, Tsochatzis E, Kafiri, Manesis E, Archimandritis A. Apoptotic caspase activation in sera from patients with chronic hepatitis C (CH-C), chronic hepatitis B (CH-B) or non-alcoholic steatohepatitis (NASH). *J Clin Virol*; 36 (Suppl 2):S171, 2006
31. Tsochatzis E, Papatheodoridis G, Hadziyannis E, Georgiou A, Chrysanthos N, Kafiri, Manesis E, Archimandritis A. Serum adiponectin levels are associated with the severity of liver steatosis in chronic viral hepatitis. *J Clin Virol*; 36 (Suppl 2):S191, 2006
32. Hadziyannis SJ, Costamena A, Katsikadelli E and Hadziyannis E. HBV surface and core protein expression in the liver in chronic hepatitis B under long term antiviral therapy. 56th Annual Meeting of the American Association for the Study of Liver Diseases abstr. 963. *Hepatology*; 44, No 4, P: 545A, 2006
33. Tsochatzis E, Papatheodoridis G, , Manesis E A, Chrysanthos N, Kafiri, Petraki K, Hadziyannis E, Pantelidaki H, Zafiropoulou R, Koskinas J, Savvas S, Archimandritis A. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly due to metabolic factors. 56th Annual Meeting of the American Association for the Study of Liver Diseases. *Hepatology*; 44, No 4, P: 552A-653A, 2006

34. Manesis EK, Schina M, Gault E, , Agelopoulou O, Papaioannou C, Kalligeros C, Arseniou V, Manolakopoulos S, Hadziyannis ES, Le Gal F, Koskinas J, Papatheodoridis G, Archimandritis A. Monitoring interferon and lamivudine treatment by quantitative measurement of HBsAg and HDV-RNA in HBeAg-negative patients with chronic hepatitis delta. *Hepatology* 56 (S1) 56th Annual Meeting of the American Association for the Study of Liver Diseases abstr. 1297. *Hepatology*; 44, No 4, P: 673A, 2006 PRESIDENTS CHOICE POSTER
35. Papatheodoridis G, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Manesis E, Archimandritis A. Serum apoptotic caspase activity as marker of disease severity in chronic hepatitis C (CH-C) or non-alcoholic fatty liver disease (NAFLD). . 42<sup>nd</sup> Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, April 11-15 2007 (*J Hepatol*, S1 No1, Vol. 46:S282 – P749)
36. Tsochatzis E, Papatheodoridis G, Hadziyannis E, Georgiou A, Chrysanthos N, Georgiou A, Kafiri G, Manesis E, Archimandritis A. The significance of leptin, adiponectin, and resistin serum levels in chronic liver diseases. 42<sup>nd</sup> Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, April 11-15 2007(*J Hepatol*, S1 No1, Vol. 46:S288 – P768)
37. Papatheodoridis G, Sevastianos V, Panopoulou H, Chrysanthos N Hadziyannis E, Chologitas E, Laras A, Manesis E, Hadziyannis SJ. Longitudinal changes in serum HBV DNA levels during the natural course of HbeAg-negative chronic hepatitis B virus (HBV) infection. 42<sup>nd</sup> Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain, April 11-15 2007(*J Hepatol*, S1 No1, Vol. 46:S182
38. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Manesis EK, Archimandritis AJ. Serum apoptotic caspase activity as diagnostic marker in HBeAg-negative chronic hepatitis B virus infection. *Digestive Disease Week*. *Gastroenterology* 2007; (Suppl 2) 132:A-760. POSTER OF DISTINCTION
39. Vassilopoulos D., N. Stamoulis, E. Hadziyannis, A.I. Archimandritis. Utility of an interferon-gamma Elispot assay for mycobacterium tuberculosis

infection screening in rheumatic patients treated with anti-TNF agents. Annual European Congress of Rheumatology, Barcelona, Spain, 2007. Ann Rheum Dis 2007;66(Suppl II):194

40. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis A. Comparison between the standard tuberculin skin testing and an enzyme linked immunospot assay (ELISPOT) for the diagnosis of tuberculosis infection in rheumatic patients treated with tumor necrosis factor antagonists. 28th Annual Congress of the European Society of Mycobacteriology. Athens, 2007 (PP-19)
41. Tiniakos D, Schina M, Koskinas J, Karandrea D, Manesis E, Hadziyannis E, Savvas S, Karamanos V, Archimandritis A, Kittas C. Retinol – Binding protein 4 (RBP4) expression in non alcoholic fatty liver disease (NAFLD). European Society of Pathology, 2007 (Virchows Archiv, 451 (2):226, 2007)
42. Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Chrysanthos N, Georgiou A, Kafiri G, Manolakopoulos S, Manesis EK, Archimandritis AJ. Serum apoptotic caspase activity an accurate marker for differentiation between inactive HBV carriers and HBeAg-negative chronic hepatitis B. UEGW, 2007 (OP-G-302, Gut A69-70)
43. Tsochatzis E, Papatheodoridis G, Hadziyannis E, Georgiou A, Georgiou A, Kafiri G, Tiniakos D, Manesis E, Archimandritis A. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. UEGW, 2007 (Gut 267)
44. Koskinas J, Schina M, Manesis E, Tiniakos D, Hadziyannis E, Savvas S, Karamanos V, Archimandritis A. Retinol – Binding protein 4 in serum and liver tissue of patients with non alcoholic fatty liver disease. A new member of adipokine family 58th Annual Meeting of the American Association for the Study of Liver Diseases abstr. 1141, Boston 10-2007
45. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J et al. Long term safety of anti-TNF $\alpha$  treatment in rheumatic patients with chronic hepatitis B virus infection. Annual European Congress of Rheumatology, Paris, Ann Rheum Dis 2008;67 (Suppl II), 607
46. Manesis E, Papatheodoridis G, Hadziyannis E, Nastos T, Karayannis P. HBsAg serum levels correlate with total liver HBV DNA but not with

- cccDNA. Oral in 59th Annual Meeting of the American Association for the Study of Liver Diseases abstr 147, San Francisco 2008
47. Hadziyannis S, Costamena A, Laras A, Hadziyannis E.  
Predictors/determinants of sustained virological response (SVR) and of HBsAg loss following long term adefovir dipivoxil (ADV) therapy in HBeAg – negative chronic hepatitis B (CHB). 59th Annual Meeting of the American Association for the Study of Liver Diseases abstr 147, San Francisco 2008
48. E. Hadziyannis, V. Sevastianos, S. Georgiou, and S. J. Hadziyannis. Treatment-related compared to spontaneously- occurring HBsAg loss in HBeAg-negative chronic hepatitis B. Poster presentation AASLD Boston 2009
49. Emilia Hadziyannis, John Koskinas<sup>1</sup>, Dimitrios Vassilopoulos, Anastasia Georgiou, Athanasios Archimandritis, Stephanos J Hadziyannis Total AFP and AFP-L3% by LiBASys in individuals with persistent AFP elevation and no evidence of hepatocellular carcinoma. Poster presentation AASLD Boston 2009
50. Emanuel K. Manesis, George V. Papatheodoridis, Emilia Hadziyannis; Significance of serum HBsAg levels for the definition of the inactive hepatitis B carrier state. Abstract 483 Hepatology, Volume 52, 4 (SUPPL) AASLD 2010
51. Stephanos J. Hadziyannis, Anastasia Georgiou, Emilia Hadziyannis Long term follow up and outcome of two subsets of “inactive” HBsAg carriers. ABSTR 1409, Hepatology, Volume 52, 4 (SUPPL) AASLD 2010
52. Emilia Hadziyannis, Dimitrios Vassilopoulos, Anastasia Georgiou, Fotini Spanou, John Koskinas; Comparison of a new HCV core antigen automated immunoassay to quantitative HCV RNA measurement in patients with chronic hepatitis C ABSTR 1912 Hepatology, Volume 52, 4 (SUPPL) AASLD 2010
53. Vassilopoulos D., Kandili A., Mantzoukis D., Georgiou S., Hadziyannis E. Evaluation of a point of care test for anti-CCP antibody detection in an outpatient rheumatology clinic. Ann Rheum Dis 2011;70(Suppl3):371
54. Vassilopoulos D, Hatzara C., Kandili A, Papageorgiou M, Georgiou S, Hadziyannis E. Safety of rituximab therapy in rheumatoid arthritis patients



with current or resolved hepatitis B virus infection, *Ann Rheum Dis* 2011;70(Suppl3):609

55. Emilia Hadziyannis, Martha Minopetrou, Melanie Deutsch, Eleni Dimopoulou, Asimina Georgiadou, John Koskinas; HCV related cryoglobulinemia: an extended analysis of the type of cryoglobulins and their antigenic targets abstract 1770 AASLD 2011 *Hepatology*, volume 54, 4 (SUPPL)
56. C. Hatzara, E. Hadziyannis, A. Kandili, S. Tsikrika, M. Minopetrou, G. Georgiopoulos, D. Vassilopoulos. rate of tuberculin skin test or interferon gamma release assay conversion during anti-tumor necrosis factor therapy in rheumatic patients. *Ann Rheum Dis* 2012;71(Suppl3):658
57. Aikaterini Margariti, Emilia Hadziyannis, Anastasia Georgiou, Melanie Deutsch, Dina Tiniakos, George Papatheodoridis. Serum levels of hyaluronic acid (HA) are better predictors of fibrosis severity than liver stiffness measurements (LSMs) by transient elastography (TE) in patients with non-alcoholic fatty liver disease (NAFLD). *UEG Week 2012*
58. Emilia Hadziyannis, Aikaterini Margariti, Anastasia Georgiou, Spilios Manolakopoulos, Melanie Deutsch, Hariklia Kranidioti, Athina Katoglou, Georgia Kafiri, Dina Tiniakos, George Papatheodoridis. Serum hyaluronic acid (HA) levels as markers of fibrosis severity in patients with chronic liver diseases (CLD) of different etiologies. *Hepatology* 56 (S1) AASLD 2012
59. Aikaterini Margariti, Emilia Hadziyannis, Anastasia Georgiou, Melanie Deutsch, George Kontos, Sofia Adamidi, Dina Tiniakos, Spilios Manolakopoulos, George Papatheodoridis. Serum levels of hyaluronic acid (HA) are better predictors of fibrosis severity than liver stiffness measurements (LSMs) by transient elastography (TE) in patients with non-alcoholic fatty liver disease (NAFLD) *Hepatology* 56 (S1) abstr 1531 AASLD 2012
60. C. Hatzara, A. Kandyli, A. Georgiadou, E. Hadziyannis, D. Vassilopoulos. Frequent Conversion of Tuberculosis Screening Tests During Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatic Diseases. Abstr 1626, *Arthritis and Rheumatism* 64 (10S) ACR 2012
61. Emilia Hadziyannis, Andreas Laras, Eleni Panopoulou, Sofia Anagnostopoulou, Stephanos Hadziyannis. IL-28B Genotypes in

- Spontaneous and Treatment Induced HBsAg Clearance of Chronic Hepatitis B Patients. *Hepatology* Abstr 897, AASLD, 2013
62. G.V. Papatheodoridis, C Triantos, E. Hadziyannis, K. Zisimopoulos, A. Georgiou, K. Margariti, M. Deutsch, V. Nikolopoulou, S. Manolakopoulos. Changes of serum HBsAg levels in HBeAg-negative chronic hepatitis B patients treated with tenofovir *Hepatology* Abstr 994 AASLD, 2013
63. Spilios Manolakopoulos, Hariklia Kranidioti, Melanie Deutsch, Alexandra Alexopoulou, Anastasia Kourikou, Georgios A. Kontos, Emilia Hadziyannis, George V. Papatheodoridis. Discontinuation of Long-Term Nucleos(T)ide Analogue(S) [Na(S)] Therapy in HBeAg-Negative Chronic Hepatitis B (Chbe-) Patients Without Cirrhosis: A Prospective Study. *Gastroenterology*, Vol. 146, Issue 5, S-963, 2014.
64. Makris A, Adamidi S, Koutsianas C, Tsalapaki C, Hadziyannis E, Vassilopoulos D. Increased expression of GM-CSF secreting peripheral B cells in patients with rheumatoid arthritis. *Ann Rheum Dis* 2014;73 (Suppl. 2): 839 (AB0108).
65. Lazaros G., Vasileiou P., Tsioufis C., Hadziyannis E., Kasiakogias A., Georgiopoulos G., Kallikazaros I., Vassilopoulos D., Stefanadis C. Interleukin-8 as a predictor of acute idiopathic pericarditis recurrences. A pilot study. European Society of Cardiology Meeting, Barcelona, August 30-September 3, 2014. *European Heart Journal* 2014;35:708.
66. George V. Papatheodoridis, Christos K. Triantos, Emilia Hadziyannis, Konstantinos Zisimopoulos, Anastasia Georgiou, Theodoros Voulgaris, Jiannis Vlachogiannakos, Vasiliki Nikolopoulou, Spilios Manolakopoulos. Interferon-inducible protein 10 (IP10) serum levels predict the decline of HBsAg serum levels in HBeAg-negative chronic hepatitis B (CHBe-) patients treated with tenofovir disoproxil fumarate (TDF) Abstr 1890 *Hepatology*, volume 60, number 4 (suppl): 1110A, AASLD 2014
67. Sofia Adamidi, Anastasia Makris, Christos Koutsianas, Christina Tsalapaki, Emilia Hadziyannis and Dimitrios Vassilopoulos. Patients with Active Rheumatoid Arthritis Display an Expanded Population of GM-CSF Expressing Peripheral B Cells. Abstr 1466 *Arthritis & Rheumatology* Volume 66, Number 11 (Supplement): S645, ACR 2014

Abstracts in Greek Medical Conferences: 62

**Total Citations: 987**

**Membership in Scientific Societies**

Greek: Athens Medical Association (1990), Hellenic Microbiological Society (1999), Hellenic Association for the Study of the Liver (2009), Hellenic Society of Virology (2014)

International: American Association for the Advancement of Science (1993), College of American Pathologists (1994), American Society of Clinical Pathologists (1994), American Medical Association (1994), American Society for Microbiology (1997)